Bristol-Myers Squibb's $74 billion acquisition of Celgene would combine two troubled companies

Bristol Myers-Squibb is acquiring Celgene in a cash and stock deal valued at $74 billion. Some view the deal as an act of survival.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.